The vessel wall: A forgotten player in post thrombotic syndrome

Scott DeRoo; K. Barry Deatrick; Peter K. Henke

doi:10.1160/TH10-03-0183

Thrombosis and Haemostasis, Table of Contents

Thromb Haemost 2010; 104(04): 681-692
DOI: 10.1160/TH10-03-0183

Review Article

Schattauer GmbH

The vessel wall: A forgotten player in post thrombotic syndrome

Scott DeRoo

¹Section of Vascular Surgery, Department of Surgery, University of Michigan, Ann Arbor, Michigan, USA

,

K. Barry Deatrick

¹Section of Vascular Surgery, Department of Surgery, University of Michigan, Ann Arbor, Michigan, USA

,

Peter K. Henke

¹Section of Vascular Surgery, Department of Surgery, University of Michigan, Ann Arbor, Michigan, USA

› Author Affiliations

Abstract

Summary

Much research in venous thrombotic diseases focuses on the acute thrombotic process such as anticoagulation and risk factors. Deep-vein thrombosis directly leads to post thrombotic syndrome, and this can cause significant patient disability. Little research has focused on the vein wall injury response to the thrombotic inflammatory insult. Herein, we review what is currently known about this process with emphasis on the matrix, mediators, and vascular medial smooth muscle response after thrombotic injury. Translational therapies and potential future agents are reviewed.

Keywords

Cell-matrix interactions - deep-vein thrombosis - inflammation - matrix metalloproteinases

Full Text

References

References
1 Lloyd-Jones D, Adams RJ, Brown TM. et al. Heart disease and stroke statistics--2010 update: a report from the American Heart Association.. Circulation 2010; 121: e46-e215.
2 Bergan JJ, Schmid-Schonbein GW, Smith PD. et al. Chronic venous disease.. N Engl J Med 2006; 355: 488-498.
3 Prandoni P, Lensing AW, Cogo A. et al. The long-term clinical course of acute deep venous thrombosis.. Ann Intern Med 1996; 125: 1-7.
4 Delis KT, Bountouroglou D, Mansfield AO. Venous claudication in iliofemoral thrombosis: long-term effects on venous hemodynamics, clinical status, and quality of life.. Ann Surg 2004; 239: 118-126.
5 Tsai S, Dubovoy A, Wainess R. et al. Severe chronic venous insufficiency: magnitude of the problem and consequences.. Ann Vasc Surg 2005; 19: 705-711.
6 Patterson BO, Hinchliffe R, Loftus IM. et al. Indications for catheter-directed thrombolysis in the management of acute proximal deep venous thrombosis.. Arterioscler Thromb Vasc Biol 2010; 30: 669-674.
7 Gasparis AP, Awadallah M, Meisner RJ. et al. Recurrent popliteal vein aneurysm.. J Vasc Surg 2010; 51: 453-457.
8 Kahn SR. How I treat postthrombotic syndrome.. Blood 2009; 114: 4624-4631.
9 Deatrick KB, Eliason JL, Lynch EM. et al. Vein wall remodeling after deep vein thrombosis involves matrix metalloproteinases and late fibrosis in a mouse model.. J Vasc Surg 2005; 42: 140-148.
10 Henke PK, Pearce CG, Moaveni DM. et al. Targeted deletion of CCR2 impairs deep vein thombosis resolution in a mouse model.. J Immunol 2006; 177: 3388-3397.
11 Henke PK, Wakefield T. Thrombus resolution and vein wall injury: dependence on chemokines and leukocytes.. Thromb Res 2009; 123 (04) S72-78.
12 Roumen-Klappe EM, Janssen MC, Van Rossum J. et al. Inflammation in deep vein thrombosis and the development of post-thrombotic syndrome: a prospective study.. J Thromb Haemost 2009; 7: 582-587.
13 Shbaklo H, Holcroft CA, Kahn SR. Levels of inflammatory markers and the development of the post-thrombotic syndrome.. Thromb Haemost 2009; 101: 505-512.
14 Varma MR, Varga AJ, Knipp BS. et al. Neutropenia impairs venous thrombosis resolution in the rat.. J Vasc Surg 2003; 38: 1090-1098.
15 Henke PK, Varma MR, Moaveni DK. et al. Fibrotic injury after experimental deep vein thrombosis is determined by the mechanism of thrombogenesis.. Thromb Haemost 2007; 98: 1045-1055.
16 Sevitt S. The mechanisms of canalisation in deep vein thrombosis.. J Pathol 1973; 110: 153-165.
17 Wakefield TW, Strieter RM, Wilke CA. et al. Venous thrombosis-associated inflammation and attenuation with neutralizing antibodies to cytokines and adhesion molecules.. Arterioscler Thromb Vasc Biol 1995; 15: 258-268.
18 Henke PK, Varma MR, Deatrick KB. et al. Neutrophils modulate post-thrombotic vein wall remodeling but not thrombus neovascularization.. Thromb Haemost 2006; 95: 272-281.
19 Wang Y, Bai Y, Qin L. et al. Interferon-gamma induces human vascular smooth muscle cell proliferation and intimal expansion by phosphatidylinositol 3-kinase dependent mammalian target of rapamycin raptor complex 1 activation.. Circ Res 2007; 101: 560-569.
20 Yoshida T, Gan Q, Shang Y. et al. Platelet-derived growth factor-BB represses smooth muscle cell marker genes via changes in binding of MKL factors and hi-stone deacetylases to their promoters.. Am J Physiol Cell Physiol 2007; 292: C886-895.
21 Owens GK, Kumar MS, Wamhoff BR. Molecular regulation of vascular smooth muscle cell differentiation in development and disease.. Physiol Rev 2004; 84: 767-801.
22 Aguilera CM, George SJ, Johnson JL. et al. Relationship between type IV collagen degradation, metalloproteinase activity and smooth muscle cell migration and proliferation in cultured human saphenous vein.. Cardiovasc Res 2003; 58: 679-688.
23 Thyberg J, Hultgardh-Nilsson A. Fibronectin and the basement membrane components laminin and collagen type IV influence the phenotypic properties of subcultured rat aortic smooth muscle cells differently.. Cell Tissue Res 1994; 276: 263-271.
24 Visse R, Nagase H. Matrix metalloproteinases and tissue inhibitors of metalloproteinases: structure, function, and biochemistry.. Circ Res 2003; 92: 827-839.
25 Galis ZS, Khatri JJ. Matrix metalloproteinases in vascular remodeling and athero-genesis: the good, the bad, and the ugly.. Circ Res 2002; 90: 251-262.
26 Zhang F, Tsai S, Kato K. et al. Transforming growth factor-beta promotes recruitment of bone marrow cells and bone marrow-derived mesenchymal stem cells through stimulation of MCP-1 production in vascular smooth muscle cells.. J Biol Chem 2009; 284: 17564-17574.
27 Schecter AD, Berman AB, Taubman MB. Chemokine receptors in vascular smooth muscle.. Microcirculation 2003; 10: 265-272.
28 Seino Y, Ikeda U, Takahashi M. et al. Expression of monocyte chemoattractant protein-1 in vascular tissue.. Cytokine 1995; 7: 575-579.
29 Humphries J, McGuinness CL, Smith A. et al. Monocyte chemotactic protein-1 (MCP-1) accelerates the organization and resolution of venous thrombi.. J Vasc Surg 1999; 30: 894-899.
30 Porreca E, Di Febbo C, Reale M. et al. Monocyte chemotactic protein 1 (MCP-1) is a mitogen for cultured rat vascular smooth muscle cells.. J Vasc Res 1997; 34: 58-65.
31 Viedt C, Vogel J, Athanasiou T. et al. Monocyte chemoattractant protein-1 induces proliferation and interleukin-6 production in human smooth muscle cells by differential activation of nuclear factor-kappaB and activator protein-1.. Arterioscler Thromb Vasc Biol 2002; 22: 914-920.
32 Ikeda U, Okada K, Ishikawa S. et al. Monocyte chemoattractant protein 1 inhibits growth of rat vascular smooth muscle cells.. Am J Physiol 1995; 268: H1021-1026.
33 Hayes IM, Jordan NJ, Towers S. et al. Human vascular smooth muscle cells express receptors for CC chemokines.. Arterioscler Thromb Vasc Biol 1998; 18: 397-403.
34 Egashira K, Zhao Q, Kataoka C. et al. Importance of monocyte chemoattractant protein-1 pathway in neointimal hyperplasia after periarterial injury in mice and monkeys.. Circ Res 2002; 90: 1167-1172.
35 Roque M, Kim WJ, Gazdoin M. et al. CCR2 deficiency decreases intimal hyperplasia after arterial injury.. Arterioscler Thromb Vasc Biol 2002; 22: 554-559.
36 Schober A, Zernecke A, Liehn EA. et al. Crucial role of the CCL2/CCR2 axis in neointimal hyperplasia after arterial injury in hyperlipidemic mice involves early monocyte recruitment and CCL2 presentation on platelets.. Circ Res 2004; 95: 1125-1133.
37 Schober A, Zernecke A. Chemokines in vascular remodeling.. Thromb Haemost 2007; 97: 730-737.
38 Diao Y, Guthrie S, Xia SL. et al. Long-term engraftment of bone marrow-derived cells in the intimal hyperplasia lesion of autologous vein grafts.. Am J Pathol 2008; 172: 839-848.
39 Caplice NM, Bunch TJ, Stalboerger PG. et al. Smooth muscle cells in human coronary atherosclerosis can originate from cells administered at marrow transplantation.. Proc Natl Acad Sci USA 2003; 100: 4754-4759.
40 Ruiz-Ortega M, Rodriguez-Vita J, Sanchez-Lopez E. et al. TGF-beta signaling in vascular fibrosis.. Cardiovasc Res 2007; 74: 196-206.
41 Annes JP, Munger JS, Rifkin DB. Making sense of latent TGFbeta activation.. J Cell Sci 2003; 116: 217-224.
42 Sajid M, Hu Z, Guo H, Li H, Stouffer GA. Vascular expression of integrin-associated protein and thrombospondin increase after mechanical injury.. J Investig Med 2001; 49: 398-406.
43 McCaffrey TA, Consigli S, Du B. et al. Decreased type II/type I TGF-beta receptor ratio in cells derived from human atherosclerotic lesions. Conversion from an antiproliferative to profibrotic response to TGF-beta1.. J Clin Invest 1995; 96: 2667-2675.
44 Edwards DR, Murphy G, Reynolds JJ. et al. Transforming growth factor beta modulates the expression of collagenase and metalloproteinase inhibitor.. EMBO J 1987; 6: 1899-1904.
45 Lutgens E, Gijbels M, Smook M. et al. Transforming growth factor-beta mediates balance between inflammation and fibrosis during plaque progression.. Arterioscler Thromb Vasc Biol 2002; 22: 975-982.
46 Kobayashi K, Yokote K, Fujimoto M. et al. Targeted disruption of TGF-beta-Smad3 signaling leads to enhanced neointimal hyperplasia with diminished matrix deposition in response to vascular injury.. Circ Res 2005; 96: 904-912.
47 Adam PJ, Regan CP, Hautmann MB. et al. Positive- and negative-acting Kruppel-like transcription factors bind a transforming growth factor beta control element required for expression of the smooth muscle cell differentiation marker SM22alpha in vivo.. J Biol Chem 2000; 275: 37798-37806.
48 Hautmann MB, Madsen CS, Owens GK. A transforming growth factor beta (TGFbeta) control element drives TGFbeta-induced stimulation of smooth muscle alpha-actin gene expression in concert with two CArG elements.. J Biol Chem 1997; 272: 10948-10956.
49 Berk BC. Vascular smooth muscle growth: autocrine growth mechanisms.. Physiol Rev 2001; 81: 999-1030.
50 Henke PK, Varma MR, Moaveni DK. et al. Fibrotic injury after experimental deep vein thrombosis is determined by the mechanism of thrombogenesis.. Thromb Haemost 2007; 98: 1045-1055.
51 Lindner V, Lappi DA, Baird A. et al. Role of basic fibroblast growth factor in vascular lesion formation.. Circ Res. 1991; 68: 106-113.
52 Jackson CL, Reidy MA. Basic fibroblast growth factor: its role in the control of smooth muscle cell migration.. Am J Pathol 1993; 143: 1024-1031.
53 Rauch BH, Millette E, Kenagy RD. et al. Thrombin- and factor Xa-induced DNA synthesis is mediated by transactivation of fibroblast growth factor receptor-1 in human vascular smooth muscle cells.. Circ Res 2004; 94: 340-345.
54 Millette E, Rauch BH, Kenagy RD. et al. Platelet-derived growth factor-BB trans-activates the fibroblast growth factor receptor to induce proliferation in human smooth muscle cells.. Trends Cardiovasc Med 2006; 16: 25-28.
55 Chen PY, Simons M, Friesel R. FRS2 via fibroblast growth factor receptor 1 is required for platelet-derived growth factor receptor beta-mediated regulation of vascular smooth muscle marker gene expression.. J Biol Chem 2009; 284: 15980-15992.
56 Heldin CH, Westermark B. Mechanism of action and in vivo role of platelet-derived growth factor.. Physiol Rev 1999; 79: 1283-1316.
57 Raines EW, Bowen-Pope DF, Ross R. Platelet-Derived Growth Factor.. Vol 95 pt. I. Heidelberg: Springer-Verlad; 1990
58 Nilsson J, Sjolund M, Palmberg L. et al. Arterial smooth muscle cells in primary culture produce a platelet-derived growth factor-like protein.. Proc Natl Acad Sci USA 1985; 82: 4418-4422.
59 Shimokado K, Raines EW, Madtes DK. et al. A significant part of macrophage-derived growth factor consists of at least two forms of PDGF.. Cell 1985; 43: 277-286.
60 Kaplan DR, Chao FC, Stiles CD. et al. Platelet alpha granules contain a growth factor for fibroblasts.. Blood 1979; 53: 1043-1052.
61 Corjay MH, Blank RS, Owens GK. Platelet-derived growth factor-induced destabilization of smooth muscle alpha-actin mRNA.. J Cell Physiol 1990; 145: 391-397.
62 Regan CP, Adam PJ, Madsen CS. et al. Molecular mechanisms of decreased smooth muscle differentiation marker expression after vascular injury.. J Clin Invest 2000; 106: 1139-1147.
63 Yang Z, Oemar BS, Carrel T. et al. Different proliferative properties of smooth muscle cells of human arterial and venous bypass vessels: role of PDGF receptors, mitogen-activated protein kinase, and cyclin-dependent kinase inhibitors.. Circulation 1998; 97: 181-187.
64 Yoshida T, Kaestner KH, Owens GK. Conditional deletion of Kruppel-like factor 4 delays downregulation of smooth muscle cell differentiation markers but accelerates neointimal formation following vascular injury.. Circ Res 2008; 102: 1548-1557.
65 Tanner FC, Meier P, Greutert H. et al. Nitric oxide modulates expression of cell cycle regulatory proteins: a cytostatic strategy for inhibition of human vascular smooth muscle cell proliferation.. Circulation 2000; 101: 1982-1989.
66 Blank RS, Owens GK. Platelet-derived growth factor regulates actin isoform expression and growth state in cultured rat aortic smooth muscle cells.. J Cell Physiol 1990; 142: 635-642.
67 Kumar MS, Hendrix JA, Johnson AD. et al. Smooth muscle alpha-actin gene requires two E-boxes for proper expression in vivo and is a target of class I basic helix-loop-helix proteins.. Circ Res 2003; 92: 840-847.
68 Liu Y, Sinha S, Owens G. A transforming growth factor-beta control element required for SM alpha-actin expression in vivo also partially mediates GKLF-dependent transcriptional repression.. J Biol Chem 2003; 278: 48004-48011.
69 Deaton RA, Gan Q, Owens GK. Sp1-dependent activation of KLF4 is required for PDGF-BB-induced phenotypic modulation of smooth muscle.. Am J Physiol Heart Circ Physiol 2009; 296: H1027-1037.
70 Subbarao K, Jala VR, Mathis S. et al. Role of leukotriene B4 receptors in the development of atherosclerosis: potential mechanisms.. Arterioscler Thromb Vasc Biol 2004; 24: 369-375.
71 Hultgardh-Nilsson A, Durbeej M. Role of the extracellular matrix and its receptors in smooth muscle cell function: implications in vascular development and disease.. Curr Opin Lipidol 2007; 18: 540-545.
72 Hedin U, Roy J, Tran PK. et al. Control of smooth muscle cell proliferation--the role of the basement membrane.. Thromb Haemost. 1999; 82 (01) 23-26.
73 Koyama H, Raines EW, Bornfeldt KE. et al. Fibrillar collagen inhibits arterial smooth muscle proliferation through regulation of Cdk2 inhibitors.. Cell 1996; 87: 1069-1078.
74 Alberts BJA, Lewis J, Raff M. et al. Molecular Biology of the Cell.. 5 ed. New York: Garland Science; 2008
75 Snow AD, Bolender RP, Wight TN. et al. Heparin modulates the composition of the extracellular matrix domain surrounding arterial smooth muscle cells.. Am J Pathol 1990; 137: 313-330.
76 Fukai N, Kenagy RD, Chen L. et al. Syndecan-1: an inhibitor of arterial smooth muscle cell growth and intimal hyperplasia.. Arterioscler Thromb Vasc Biol 2009; 29: 1356-1362.
77 Myers Jr DD, Henke PK, Bedard PW. et al. Treatment with an oral small molecule inhibitor of P selectin (PSI-697) decreases vein wall injury in a rat stenosis model of venous thrombosis.. J Vasc Surg 2006; 44: 625-632.
78 See-Tho K, Harris EJ. Jr. Thrombosis with outflow obstruction delays thrombolysis and results in chronic wall thickening of rat veins.. J Vasc Surg 1998; 28: 115-123.
79 Sansilvestri-Morel P, Rupin A, Jaisson S. et al. Synthesis of collagen is dysregulated in cultured fibroblasts derived from skin of subjects with varicose veins as it is in venous smooth muscle cells.. Circulation 2002; 106: 479-483.
80 Sansilvestri-Morel P, Rupin A, Badier-Commander C. et al. Imbalance in the synthesis of collagen type I and collagen type III in smooth muscle cells derived from human varicose veins.. J Vasc Res 2001; 38: 560-568.
81 Hedin U, Bottger BA, Forsberg E. et al. Diverse effects of fibronectin and laminin on phenotypic properties of cultured arterial smooth muscle cells.. J Cell Biol 1988; 107: 307-319.
82 Chiang HY, Korshunov VA, Serour A. et al. Fibronectin is an important regulator of flow-induced vascular remodeling.. Arterioscler Thromb Vasc Biol 2009; 29: 1074-1079.
83 Taillefer R. Radiolabeled peptides in the detection of deep venous thrombosis.. Semin Nucl Med 2001; 31: 102-123.
84 Raffetto JD, Khalil RA. Matrix metalloproteinases in venous tissue remodeling and varicose vein formation.. Curr Vasc Pharmacol 2008; 6: 158-172.
85 Cho A, Graves J, Reidy MA. Mitogen-activated protein kinases mediate matrix metalloproteinase-9 expression in vascular smooth muscle cells.. Arterioscler Thromb Vasc Biol 2000; 20: 2527-2532.
86 Ma C, Chegini N. Regulation of matrix metalloproteinases (MMPs) and their tissue inhibitors in human myometrial smooth muscle cells by TGF-beta1.. Mol Hum Reprod 1999; 5: 950-954.
87 Gurjar MV, DeLeon J, Sharma RV. et al. Mechanism of inhibition of matrix metalloproteinase-9 induction by NO in vascular smooth muscle cells.. J Appl Physiol 2001; 91: 1380-1386.
88 Gurjar MV, Deleon J, Sharma RV. et al. Role of reactive oxygen species in IL-1 beta-stimulated sustained ERK activation and MMP-9 induction.. Am J Physiol Heart Circ Physiol 2001; 281: H2568-2574.
89 Weiss SJ. Tissue destruction by neutrophils.. N Engl J Med 1989; 320: 365-376.
90 Galis ZS, Muszynski M, Sukhova GK. et al. Cytokine-stimulated human vascular smooth muscle cells synthesize a complement of enzymes required for extracellular matrix digestion.. Circ Res 1994; 75: 181-189.
91 Turner NA, Hall KT, Ball SG. et al. Selective gene silencing of either MMP-2 or MMP-9 inhibits invasion of human saphenous vein smooth muscle cells.. Atherosclerosis 2007; 193: 36-43.
92 Rotmans JI, Velema E, Verhagen HJ. et al. Matrix metalloproteinase inhibition reduces intimal hyperplasia in a porcine arteriovenous-graft model.. J Vasc Surg 2004; 39: 432-439.
93 Bendeck MP, Irvin C, Reidy MA. Inhibition of matrix metalloproteinase activity inhibits smooth muscle cell migration but not neointimal thickening after arterial injury.. Circ Res 1996; 78: 38-43.
94 Dwivedi A, Slater SC, George SJ. MMP-9 and –12 cause N-cadherin shedding and thereby beta-catenin signalling and vascular smooth muscle cell proliferation.. Cardiovasc Res 2009; 81: 178-186.
95 Stefanidakis M, Koivunen E. Cell-surface association between matrix metalloproteinases and integrins: role of the complexes in leukocyte migration and cancer progression.. Blood 2006; 108: 1441-1450.
96 Tu G, Xu W, Huang H. et al. Progress in the development of matrix metalloproteinase inhibitors.. Curr Med Chem 2008; 15: 1388-1395.
97 Baxter BT, Pearce WH, Waltke EA. et al. Prolonged administration of doxycycline in patients with small asymptomatic abdominal aortic aneurysms: report of a prospective (Phase II) multicenter study.. J Vasc Surg 2002; 36: 1-12.
98 Sood V, Luke C, Miller E. et al. Vein wall remodeling after deep vein thrombosis: differential effects of low molecular weight heparin and doxycycline.. Ann Vasc Surg 2010; 24: 233-241.
99 Singh I, Burnand KG, Collins M. et al. Failure of thrombus to resolve in urokinase-type plasminogen activator gene-knockout mice: rescue by normal bone marrow-derived cells.. Circulation 2003; 107: 869-875.
100 Henke PK. Plasmin and matrix metalloproteinase system in deep venous thrombosis resolution.. Vascular 2007; 15: 366-371.
101 Vassalli JD, Sappino AP, Belin D. The plasminogen activator/plasmin system.. J Clin Invest 1991; 88: 1067-1072.
102 Carmeliet P, Bouche A, De Clercq C. et al. Biological effects of disruption of the tissue-type plasminogen activator, urokinase-type plasminogen activator, and plasminogen activator inhibitor-1 genes in mice.. Ann NY Acad Sci 1995; 748: 367-382.
103 Carmeliet P, Moons L, Herbert JM. et al. Urokinase but not tissue plasminogen activator mediates arterial neointima formation in mice.. Circ Res 1997; 81: 829-839.
104 Lijnen HR, Van Hoef B, Lupu F. et al. Function of the plasminogen/plasmin and matrix metalloproteinase systems after vascular injury in mice with targeted inactivation of fibrinolytic system genes.. Arterioscler Thromb Vasc Biol 1998; 18: 1035-1045.
105 Roztocil E, Nicholl SM, Davies MG. Mechanisms of kringle fragment of urokinase-induced vascular smooth muscle cell migration.. J Surg Res 2007; 141: 83-90.
106 Roztocil E, Nicholl SM. Galaria, II, et al. Plasmin-induced smooth muscle cell proliferation requires epidermal growth factor activation through an extracellular pathway.. Surgery 2005; 138: 180-186.
107 Nicholl SM, Roztocil E, Davies MG. Urokinase-induced smooth muscle cell responses require distinct signaling pathways: a role for the epidermal growth factor receptor.. J Vasc Surg 2005; 41: 672-681.
108 Bakken AM, Protack CD, Roztocil E. et al. Cell migration in response to the amino-terminal fragment of urokinase requires epidermal growth factor receptor activation through an ADAM-mediated mechanism.. J Vasc Surg 2009; 49: 1296-1303.
109 Wakefield TW, Myers DD, Henke PK. Mechanisms of venous thrombosis and resolution.. Arterioscler Thromb Vasc Biol 2008; 28: 387-391.
110 Otsuka G, Stempien-Otero A, Frutkin AD. et al. Mechanisms of TGF-beta1-induced intimal growth: plasminogen-independent activities of plasminogen activator inhibitor-1 and heterogeneous origin of intimal cells.. Circ Res 2007; 100: 1300-1307.
111 Otsuka G, Agah R, Frutkin AD. et al. Transforming growth factor beta 1 induces neointima formation through plasminogen activator inhibitor-1-dependent pathways.. Arterioscler Thromb Vasc Biol 2006; 26: 737-743.
112 Peng L, Bhatia N, Parker AC. et al. Endogenous vitronectin and plasminogen activator inhibitor-1 promote neointima formation in murine carotid arteries.. Arterioscler Thromb Vasc Biol 2002; 22: 934-939.
113 de Waard V, Arkenbout EK, Carmeliet P. et al. Plasminogen activator inhibitor 1 and vitronectin protect against stenosis in a murine carotid artery ligation model.. Arterioscler Thromb Vasc Biol 2002; 22: 1978-1983.
114 Kouri FM, Queisser MA, Konigshoff M. et al. Plasminogen activator inhibitor type 1 inhibits smooth muscle cell proliferation in pulmonary arterial hypertension.. Int J Biochem Cell Biol 2008; 40: 1872-1882.
115 Otsuka G, Stempien-Otero A, Frutkin AD. et al. Mechanisms of TGF-{beta}1-Induced Intimal Growth. Plasminogen-Independent Activities of Plasminogen Activator Inhibitor-1 and Heterogeneous Origin of Intimal Cells.. Circ Res 2007; 100: 1300-1307.
116 Suzuki J, Ogawa M, Muto S. et al. The effects of pharmacological PAI-1 inhibition on thrombus formation and neointima formation after arterial injury.. Expert Opin Ther Targets 2008; 12: 783-794.
117 Carmeliet P, Moons L, Lijnen R. et al. Inhibitory role of plasminogen activator inhibitor-1 in arterial wound healing and neointima formation: a gene targeting and gene transfer study in mice.. Circulation 1997; 96: 3180-3191.
118 Bond M, Wu YJ, Sala-Newby GB. et al. Rho GTPase, Rac1, regulates Skp2 levels, vascular smooth muscle cell proliferation, and intima formation in vitro and in vivo.. Cardiovasc Res 2008; 80: 290-298.
119 Alevriadou BR. CAMs and Rho small GTPases: gatekeepers for leukocyte transendothelial migration. Focus on “VCAM-1-mediated Rac signaling controls endothelial cell-cell contacts and leukocyte transmigration”.. Am J Physiol Cell Physiol 2003; 285: C250-252.
120 Diebold I, Djordjevic T, Hess J. et al. Rac-1 promotes pulmonary artery smooth muscle cell proliferation by upregulation of plasminogen activator inhibitor-1: role of NFkappaB-dependent hypoxia-inducible factor-1alpha transcription.. Thromb Haemost 2008; 100: 1021-1028.
121 Patterson C, Stouffer GA, Madamanchi N. et al. New tricks for old dogs: nonthrombotic effects of thrombin in vessel wall biology.. Circ Res 2001; 88: 987-997.
122 Liu MW, Roubin GS, King SB. 3rd. Restenosis after coronary angioplasty. Potential biologic determinants and role of intimal hyperplasia.. Circulation 1989; 79: 1374-1387.
123 Garg UC, Hassid A. Nitric oxide-generating vasodilators and 8-bromo-cyclic guanosine monophosphate inhibit mitogenesis and proliferation of cultured rat vascular smooth muscle cells.. J Clin Invest 1989; 83: 1774-1777.
124 Moaveni DK, Lynch EM, Luke C. et al. Vein wall re-endothelialization after deep vein thrombosis is improved with low-molecular-weight heparin.. J Vasc Surg 2008; 47: 616-624.
125 Largiader T, Eto M, Payeli SK. et al. Endothelial nitric oxide synthase gene transfer inhibits human smooth muscle cell migration via inhibition of Rho A.. J Cardiovasc Pharmacol 2008; 52: 369-374.
126 Ren XD, Kiosses WB, Schwartz MA. Regulation of the small GTP-binding protein Rho by cell adhesion and the cytoskeleton.. EMBO J 1999; 18: 578-585.
127 Somlyo AP, Somlyo AV. Signal transduction by G-proteins, rho-kinase and protein phosphatase to smooth muscle and non-muscle myosin II.. J Physiol 2000; 522: 177-185.
128 Modarai B, Burnand KG, Sawyer B. et al. Endothelial progenitor cells are recruited into resolving venous thrombi.. Circulation 2005; 111: 2645-2653.
129 Hirschi KK, D’Amore PA. Pericytes in the microvasculature.. Cardiovasc Res 1996; 32: 687-698.
130 Corselli M, Chien-Wen C, Crisan M. et al. Perivascular Ancestors of Adult Multi-potent Stem Cells.. Arterioscl Thromb Vasc Biol 2010; 30: 1104-1109.
131 Dore-Duffy P, Owen C, Balabanov R. et al. Pericyte migration from the vascular wall in response to traumatic brain injury.. Microvasc Res 2000; 60: 55-69.
132 Juchem G, Weiss DR, Gansera B. et al. Pericytes in the macrovascular intima: possible physiological and pathogenetic impact.. Am J Physiol Heart Circ Physiol 2010; 298: H754-770.
133 Wakefield TW, Myers D, Henke P. Role of selectins and fibrinolysis in VTE.. Thrombosis Res 2009: S35-S40.
134 Myers D, Wrobleski S, Londy F. et al. New and effective treatment of experimentally induced venous thrombosis with anti-inflammatory rPSGL-Ig.. Thromb Haemost 2002; 87: 374-382.
135 Comerota AJ. Quality-of-life improvement using thrombolytic therapy for iliofe-moral deep venous thrombosis.. Rev Cardiovasc Med 2002; 3 (02) S61-67.
136 Glynn RJ, Danielson E, Fonseca FA. et al. A Randomized Trial of Rosuvastatin in the Prevention of Venous Thromboembolism.. N Engl J Med 2009; 360: 1851-1861.
137 Katsenis K. Micronized purified flavonoid fraction (MPFF): a review of its pharmacological effects, therapeutic efficacy and benefits in the management of chronic venous insufficiency.. Curr Vasc Pharmacol 2005; 3: 1-9.
138 Kahn SR. How I manage the post thrombotic syndrome.. Blood 2009; 114: 4624-4631.
139 Merli G, Spyropoulos AC, Caprini JA. Use of emerging oral anticoagulants in clinical practice: translating results from clinical trials to orthopedic and general surgical patient populations.. Ann Surg 2009; 250: 219-228.